163 related articles for article (PubMed ID: 29726479)
1. Prognostic factors in adrenocortical carcinoma: data from a large Polish series.
Nowak KM; Samsel R; Cichocki A; Ambroziak U; Roszkowska-Purska K; Łebek-Szatańska A; Koperski Ł; Otto M; Zgliczyński W; Papierska L
Pol Arch Intern Med; 2018 Jun; 128(6):371-378. PubMed ID: 29726479
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
Guelho D; Paiva I; Vieira A; Carrilho F
Endocrinol Nutr; 2016 May; 63(5):212-9. PubMed ID: 26969077
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
Tőke J; Uhlyarik A; Lohinszky J; Stark J; Huszty G; Micsik T; Borka K; Reismann P; Horányi J; Igaz P; Tóth M
Front Endocrinol (Lausanne); 2022; 13():952418. PubMed ID: 36246926
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
[TBL] [Abstract][Full Text] [Related]
7. New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
Puglisi S; Calabrese A; Ferraù F; Violi MA; Laganà M; Grisanti S; Ceccato F; Scaroni C; Di Dalmazi G; Stigliano A; Altieri B; Canu L; Loli P; Pivonello R; Arvat E; Morelli V; Perotti P; Basile V; Berchialla P; Urru S; Fiori C; Porpiglia F; Berruti A; Pia A; Reimondo G; Cannavò S; Terzolo M
J Clin Endocrinol Metab; 2023 Sep; 108(10):2517-2525. PubMed ID: 37022947
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
[TBL] [Abstract][Full Text] [Related]
10. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
11. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
12. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
13. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
14. Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.
Kim Y; Margonis GA; Prescott JD; Tran TB; Postlewait LM; Maithel SK; Wang TS; Evans DB; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem AI; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Poultsides GA; Pawlik TM
JAMA Surg; 2016 Apr; 151(4):365-73. PubMed ID: 26676603
[TBL] [Abstract][Full Text] [Related]
15. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
16. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
[TBL] [Abstract][Full Text] [Related]
17. Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience.
Pan LH; Yen CC; Huang CJ; Ng XN; Lin LY
Front Endocrinol (Lausanne); 2023; 14():1134643. PubMed ID: 36967802
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.
Liang J; Liu Z; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Wei X; Lu Y; Zhu Y
Endocrine; 2020 Feb; 67(2):449-456. PubMed ID: 31786772
[TBL] [Abstract][Full Text] [Related]
19. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.
Beuschlein F; Weigel J; Saeger W; Kroiss M; Wild V; Daffara F; Libé R; Ardito A; Al Ghuzlan A; Quinkler M; Oßwald A; Ronchi CL; de Krijger R; Feelders RA; Waldmann J; Willenberg HS; Deutschbein T; Stell A; Reincke M; Papotti M; Baudin E; Tissier F; Haak HR; Loli P; Terzolo M; Allolio B; Müller HH; Fassnacht M
J Clin Endocrinol Metab; 2015 Mar; 100(3):841-9. PubMed ID: 25559399
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
